Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, non-inferiority study

The Lancet Infectious Diseases

Volumn 12, Issue 1, 2012, Pages 27-35

  Molina, Jean Michel ^a   LaMarca, Anthony ^b   Andrade Villanueva, Jaime ^c   Clotet, Bonaventura ^d   Clumeck, Nathan ^e   Liu, Ya Pei ^f   Zhong, Lijie ^f   Margot, Nicolas ^f   Cheng, Andrew K ^f   Chuck, Steven L ^f  

^a SAINT LOUIS HOSPITAL   (France)

^b Therafirst Medical Center   (United States)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^f GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; DARUNAVIR; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; RALTEGRAVIR; RITONAVIR; TIPRANAVIR;

ABDOMINAL PAIN; ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BRONCHITIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY CARCINOMA; LIPOATROPHY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SIDE EFFECT; SINUSITIS; SUBSTANCE ABUSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INHIBITION;

ADULT; ALANINE TRANSAMINASE; ANTI-RETROVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; CD4 LYMPHOCYTE COUNT; DIARRHEA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; PYRROLIDINONES; QUINOLONES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84155164041     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70249-3     Document Type: Article

References (22)

1. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008, 82:764-774.
2. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006, 43:1-5.
3. Mathias AA, West S, Hui J, Kearney BP Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009, 85:64-70.
4. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374:796-806. for the STARTMRK investigators.
5. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008, 359:339-354.
6. Eron J, Rockstroh J, Reynes J, et al. QDMRK, a phase III study of the safety & efficacy of once daily (QD) versus twice daily (BID) raltegravir (RAL) in combination therapy for treatment-naïve HIV-infected patients (Pts). Presented at the 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-Mar 2, 2011. Abstract 150LB for the QDMRK Study Team, (accessed Sept 22, 2011). http://www.natap.org/2011/CROI/croi_61.htm.
7. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010, 201:814-822.
8. Ramanathan S, Mathias AA, German P, Kearney BP Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011, 50:229-244.
9. Ramanathan S, Mathias A, Hinkle J, Kearney BP. Clinical pharmacology of the HIV integrase inhibitor elvitegravir. Presented at the 11th European AIDS Conference; Madrid, Spain; Oct 24-27, 2007. Abstract 1711.
10. Smith F, Hammerstrom T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J 2011, 45:291-300. (accessed Sept 22, 2011). http://www.diahome.org/productfiles/8357/diaj_41391.pdf.
11. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370:29-38. on behalf of the DUET-1 study group.
12. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370:39-48. on behalf of the DUET-2 study group.
13. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008, 359:355-365.
14. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
15. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000, 44:2475-2484.
16. Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007, 369:1169-1178. on behalf of the POWER 1 and 2 study groups.
17. Gathe J, Diaz R, Fatkenheuer G, et al. Phase 3 trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone. Presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; Feb 16-19, 2010. Abstract 54LB.
18. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008, 359:1442-1455.
19. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009, 23:2289-2300.
20. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359:1429-1441.
21. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007, 370:49-58. on behalf of the TITAN study group.
22. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009, 49:1441-1449.